Immunic Inc IMUX

$7.52 -0.27 (-3.47%)

Valuation

Market cap
106,287,000
Revenue TTM
$0
Net income TTM
$-97,170,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
105,100
Avg volume
365,366
Day's range
$7.52 – $7.87
Shares out
13,644,000
Stochastic %K
26%
Beta
1.48
Analysts
Strong Buy
Price target
$43.09

Price

Company profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company...

Show more

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
332 255 9818
Website
https://www.imux.com
Address
1200 Avenue of the Americas, Suite 200, New York, United States

Latest news

Stocktwits

MrInvestor67 Nov 14, 2:03 AM
$IMUX The management reiterated timeline for topline in December means, they have all the data they need to crunch. The database unlock must have happened already or about to be unlocked this month. I wouldn’t be surprised to see topline results in first week of December.
1 replies
Mattjen Nov 13, 11:29 PM
$IMUX Morgan Stanley's IMUX ownership Reporting period Shares reported June 30, 2026 23,748 September 30, 2026 704,244 Difference +680,496
1 replies
Mattjen Nov 13, 11:27 PM
$IMUX Detail Reported Institution Morgan Stanley Beneficial ownership 704,244 shares Ownership percentage 5.2% Shared voting power 702,419 shares Shared dispositive power 704,244 shares Ownership measurement date September 30, 2026 Filing date November 13, 2026 Filing type Schedule 13G
0 replies
rizmanasjr Nov 13, 10:15 PM
$IMUX 🚀
0 replies
radonco Nov 13, 8:51 PM
$IMUX very low volume today…tick-tock
0 replies
BiotechSwings Nov 13, 2:58 PM
December is the whole story on $IMUX imo twin Phase 3 ENSURE trials, vidofludimus calcium in relapsing multiple sclerosis, topline expected next month 2,221 patients randomized across both studies. that is not a small swing closed 7.79 yesterday, softer again this morning, and the readout has not moved
2 replies
focafoca99 Nov 13, 1:26 PM
$IMUX delivers Q3 2026 earnings and corporate update via press release.
0 replies
flychicken1991 Nov 13, 11:41 AM
$IMUX Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update. Impact: Positive (77%). Reaffirmed December results timing can modestly support IMUX's share price by limiting perceived milestone-delay risk; the announcement does not establish improved odds of clinical success. Source and what to watch next: https://nimpact.tech/newsimpact/news/6717184bd6bfef9c/imux-immunic-inc-reports-third-quarter-2026-financial-results-and-provid?utm_source=stocktwits&utm_medium=story_url
0 replies